Coca-Cola European Partners PLC (CCEP)vsNovo Nordisk A/S (NVO)
CCEP
Coca-Cola European Partners PLC
$93.23
+1.06%
CONSUMER DEFENSIVE · Cap: $41.69B
NVO
Novo Nordisk A/S
$36.33
-1.52%
HEALTHCARE · Cap: $165.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 1379% more annual revenue ($309.06B vs $20.90B). NVO leads profitability with a 33.1% profit margin vs 9.3%. CCEP appears more attractively valued with a PEG of 2.62. CCEP earns a higher WallStSmart Score of 59/100 (C).
CCEP
Buy59
out of 100
Grade: C
NVO
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+57.7%
Fair Value
$230.72
Current Price
$93.23
$137.49 discount
Margin of Safety
-59.4%
Fair Value
$24.21
Current Price
$36.33
$12.12 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 68.3% YoY
Every $100 of equity generates 23 in profit
Generating 1.5B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 61 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 44.5%
Large-cap with strong market position
Areas to Watch
0.2% revenue growth
Distress zone — elevated risk
Elevated debt levels
Weak financial health signals
Weak financial health signals
Expensive relative to growth rate
Revenue declined 7.6%
Earnings declined 4.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : CCEP
The strongest argument for CCEP centers on EPS Growth, Return on Equity, Free Cash Flow.
Bull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.
Bear Case : CCEP
The primary concerns for CCEP are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
CCEP profiles as a value stock while NVO is a declining play — different risk/reward profiles.
CCEP carries more volatility with a beta of 0.39 — expect wider price swings.
CCEP is growing revenue faster at 0.2% — sustainability is the question.
CCEP generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
CCEP scores higher overall (59/100 vs 55/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Coca-Cola European Partners PLC
CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA
Coca-Cola Europacific Partners PLC produces, distributes and sells a variety of ready-to-drink non-alcoholic beverages. The company is headquartered in Uxbridge, the United Kingdom.
Visit Website →Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other BEVERAGES - NON-ALCOHOLIC Stocks
Want to dig deeper into these stocks?